Why the study?
Data are limited regarding the potential systemic effects and safety of perineural glucocorticoids used as regional anesthesia adjuvants.
Does the addition of perineural glucocorticoids to local anesthetic injection increase serum glucose, potassium, and WBC in patients undergoing total hip arthroplasty?
Does the addition of perineural glucocorticoids to local anesthetic injection increase serum glucose, potassium, and WBC in patients undergoing total hip arthroplasty?
Perineural glucocorticoid adjuvants during total hip arthroplasty cause transient, clinically insignificant elevations in serum glucose for the first two postoperative days.
Answers are grounded in this paper and cite their sources.
May elevate early postoperative glucose after THA; hypothesis-generating and requires prospective confirmation before practice change.
Purpose: Glucocorticoids are commonly used as regional anesthesia adjuvants to improve blockade quality and duration. There are limited data in the literature regarding the potential systemic effects and safety of perineural glucocorticoids. This study examines the effects of perineural glucocorticoids on serum glucose, potassium, and white blood cell count (WBC) in the immediate postoperative period after primary total hip arthroplasty (THA). Patients and Methods: A retrospective cohort study was carried out at a tertiary academic medical center utilizing electronic health records of 210 patients who underwent THA, for which patients received either a periarticular local anesthetic injection alone (PAI, N=132) or additional peripheral nerve blocks (PNB, N=78) containing 10 mg dexamethasone and 80 mg methylprednisolone acetate (PAI+PNB). The primary outcome was change in serum glucose from a preoperative baseline on postoperative days (POD) 1, 2, and 3. Secondary outcomes included changes in WBC and serum potassium. Results: The change in serum glucose from baseline was found to be significantly higher in the PAI+PNB group compared to the PAI group on POD 1 (mean difference 19.87 mg/dL, 95% CI [12.42, 27.32]; P < 0.001) and POD 2 (mean difference 17.5 mg/dL, 95% CI [9.66, 25.44], P < 0.001). No significant difference was found on POD 3 (mean difference − 8.18 mg/dL, 95% CI [− 19.07, 2.70], P =0.14). Statistically significant but clinically insignificant differences were detected in serum potassium in the PAI+PNB group compared to the PAI group on POD1 (mean difference 0.16 mEq/L, 95% CI [0.02, 0.30], P =0.03) and WBC on POD 2 (mean difference 3.18 × 1000/mm 3 , 95% CI [2.14, 4.22], P < 0.001). Conclusion: Patients who underwent THA and received PAI+PNB with glucocorticoid adjuvants demonstrated higher elevations in serum glucose for the first two PODs compared to patients who received PAI alone. These differences resolved by a third POD and are likely to be of no clinical significance.
No takes yet. Share an insight, caveat, or question.
Sharma et al. (2023) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: